ODC1 and neoplasm: The ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) has been shown to reduce the highly tumorigenic CD114+ subpopulation as well as neurosphere formation and tumor initiation in vitro and in vivo.14